Nanologica is a Swedish nanotechnology company developing nanoporous silica for purification by chromatography.

NLAB Saga^®, Nanologica’s silica-based product line, has been specifically designed for the purification of peptide drugs, such as insulin and GLP-1 analogues. NLAB Saga^® has been tested and used by pharmaceutical companies worldwide manufacturing APIs at industrial scale where quality, performance and durability are uncompromisable.

Nanologica has full control of the entire manufacturing process. The company’s proprietary production method allows for precise control of the shape, size, porosity, and surface properties of silica particles leading to an optimized combination of pore volume, high surface area and high carbon load.

This results in a robust and reliable product that can streamline production processes and reduce costs for peptide drug manufacturers. This in turn can increase the availability of cost-effective medicines and give more people around the world access to vital treatments for diabetes and obesity.